Pure Global
NCT06294548

A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC

A Phase Ib/II, Dose Escalation and Dose Expansion Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma (HCC)
University of Alabama at Birmingham·Phase 1/2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Hepatocellular Carcinoma
Drug/Device/Intervention
Valemetostat
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
University of Alabama at Birmingham
Location
Birmingham, United States of America
Timeline & enrollment
Phase
Phase 1/2
Start date
May 31, 2024
End date
Dec 31, 2027
Enrollment
45 participants
Primary outcome

Phase 1b,Phase II

Summary

This is a phase Ib/II, dose escalation and dose expansion study of valemetostat (DS-3201)
 with atezolizumab and bevacizumab in patients advanced Hepatocellular carcinoma (HCC) who did
 not receive prior systemic therapy for advanced HCC.

ICD-10 classifications
Malignant neoplasm: HepatoblastomaMalignant neoplasm: Liver cell carcinomaMalignant neoplasm: Other specified carcinomas of liverMalignant neoplasm: Liver, unspecifiedMalignant neoplasm: Hepatic flexure
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06294548
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06294548 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by University of Alabama at Birmingham and is currently Not yet recruiting. The study focuses on Hepatocellular Carcinoma. Target enrollment is 45 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.